Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Fungal Infections Drive Demand for Anti-fungal Therapies, Market to Reach US$22.8 Billion by 2033 | Future Market Insights, Inc.

This image opens in the lightbox

News provided by

Future Market Insights

14 Nov, 2023, 15:15 GMT

Share this article

Share toX

Share this article

Share toX

  • Availability and effective adoption of generic antifungal drugs and therapies enhance treatment procedures, driving market growth
  • Report covers leading companies, revenue and volume forecasts, company rankings, competitive landscape, growth factors, trends, and pricing analysis

Global Anti-fungal Therapy Market Forecast by Azoles, Polyene macrolides, and Others from 2023 to 2033.

NEWARK, Del., Nov. 14, 2023 /PRNewswire/ -- The global antifungal therapy market was valued at US$13.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2033, reaching US$22.8 billion by 2033. The azoles segment led the market by drug class in 2022, with a share of approximately 29.1%.

To get a preview of our comprehensive antifungal therapies market research report before you purchase, click here to request a sample report.

The increasing fungal disease rate has forced the patient to take anti-fungal drugs, driving the market growth. For instance, on May 20, 2020, according to Fungal Infections in Humans, around 1.7 million people die from serious fungal infections each year, which cause over 150 million cases worldwide.

The rising demand for anti-fungal drugs that can be used effectively on the body without side effects contributes to market opportunities. So, companies are focusing on research and development activities for formulation and development.  Furthermore, antifungal drugs are widely acceptable by several patients as these can be used as an effective medication for fungal infection.

Most of the anti-fungal therapies/drugs require a prescription from a doctor. However, a few are available as over-the-counter (OTC) drugs in emerging countries, expected to drive the anti-fungal therapy market during the forecast period. For instance, on 20 January 2022, according to The Economic Times report, as part of a new over-the-counter (OTC) drug policy, India will soon permit the sale of some drugs without a prescription.

Pharmaceutical manufacturers are concentrating on developing new drug discoveries, formulation of tablets, and different drug dosages. For instance, on 16 December 2022, The U.S. Food and Drug Administration granted final approval to Sun Pharma's new drug for application in antifungal medications.

Antifungal Therapies Market Research Report Scope:

Data Points

Market Insights

Anti-fungal Therapy Market Size, 2022

US$ 13.8 Billion

Anti-fungal Therapy Market Value, 2023

US$ 14.4 Billion

Anticipated Market Value, 2033

US$ 22.8 Billion

Value-based CAGR (2023 to 2033)

4.7 %

Market Share of Top 5 Countries

52.3 %

Key Market Players

- Eli Lilly and Company

- Sanofi S.A

-  Abbott Laboratories

-  Arcadia Consumer Healthcare Inc.

-  Astellas Pharma Inc

-  GlaxoSmithKline Plc

-  Merck & Co. Inc.

-  Novartis A.G

-  Gilead Sciences Inc.

-  Johnson & Johnson's

-  MerzPharma

-  Enzon Pharmaceuticals Inc.

-  Glenmark

-  Dr. Reddy's Laboratories

-  F. Hoffmann-La Roche Ltd.

-  Teva Pharmaceutical Industries Ltd.

-  Hikma Pharmaceuticals PLC

-  Sun Pharmaceutical Industries Ltd.

-  Apotex Inc.

-  Zydus Cadila

-  Aurobindo Pharma

-  Cipla Inc.

-  Dr. Reddy's Laboratories Ltd.

-  Pfizer Inc.

-  Torrent Pharmaceuticals Ltd.

-  Bayer AG.

Purchase this report now to get 20+ key companies with their Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis.

Key Takeaways from the Market Study

  • The azoles drug class is the leading market segment, holding approximately 29.1% market value, as it is known as a broad range of antibiotics used to treat systemic fungal infections.
  • The candidiasis segment leads in terms of indication with a market value of 35.0%. A fungus called Candida can majorly infect the skin and other body parts.
  • By route of administration, the topical segment is leading the global anti-fungal therapy market and is expected to continue to do so with a projected CAGR rate of 4.7% through 2033.
  • By distribution channel, retail pharmacies are leading the global anti-fungal therapy market with a share of 44.0%.
  • North America is considered the leading region with a market share of 32.2%, owing to the high prevalence of fungal diseases like histoplasma among the population.

"With increasing formulation and development, rising incidence of fungal diseases, and growing prescription rate for anti-fungal drugs, the anti-fungal therapy market is expected to witness significant expansion over the forecast period," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.).

Market Competition

The market for anti-fungal therapies is fragmented, and there exists a number of local, upcoming, as well as established players. Key players have initiated marketing initiatives to educate the elderly population about the benefits of anti-fungal therapies while also attempting to improve the drugs with different specifications.

Recent Developments

  • On July 5, 2019, Hetero Healthcare Ltd., a pharmaceutical company headquartered in Hyderabad, India, launched GOCAN I.V Fluconazole, which is an anti-fungal drug for the treatment of both systemic and superficial fungal infections.
  • On May 12, 2020, Fresenius Kabi in the United States launched an antifungal agent micafungin, which is an intravenous drug. By launching the drug, Fresenius Kabi has expanded its product portfolio in anti-fungal drugs segment.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the blood glucose monitoring devices market in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global blood glucose monitoring devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The research study is based on the drug class – (azoles, polyene macrolides, echinocandins, allylamines and others), indication (dermatophytosis, aspergillosis, candidiasis, and others), route of administration (oral, topical, and parenteral), distribution (retail pharmacies, hospital pharmacies, online pharmacies), and across seven key regions of the world.

Request a detailed research methodology for this report here!

About Healthcare Division at Future Market Insights 

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here. 

About the Author:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI's Extensive Coverage in the Healthcare Domain:

  • The dysphagia management business revenue in the United Kingdom is anticipated to rise from US$232.4 million in 2023 to US$293.3 million by 2033.
  • The global ultra-fine medical wire market, valued at US$237.9 million in 2022, is projected to reach US$466.2 million by 2033, with a compound annual growth rate (CAGR) of nearly 6.4% over the forecast period from 2023 to 2033.
  • The global anti-aging vitamins market, valued at US$1.4 billion in 2022, is anticipated to grow at a CAGR of 8.8%, reaching a valuation of US$3.5 billion by 2033.
  • Sales of hospital capacity management solutions in Europe are estimated to reach US$346.4 million in 2023, with a projected increase to surpass US$529.4 million by 2033.
  • Medical cart solutions in North America are projected to be adopted at a rate of 4.7% through 2034. The size of the medical cart industry in the region is expected to increase from US$2,255.10 million in 2023 to US$3,750.98 million by 2034.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.

Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us
Nandini Singh Sawlani  
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.